Schedule your COVID-19 vaccine wherever possible. Please do not call your doctor as they cannot schedule an appointment for you. Learn more.

MitraClip device for patients at moderate risk for surgery

Trial ID:
IRB-20-7647
Matthew J Price, M.D.
The purpose of this research is to extend the current approved indication of the MitraClip device to include patients who are considered moderate-risk candidates for traditional mitral valve repair surgery.

Inclusion Criteria

  • Must be 18 years old or older
  • Must be at moderate surgical risk for mitral valve repair
  • Must have severe mitral regurgitation
  • Be willing to participate in the trial for 10 years

Exclusion Criteria

  • Current participating in another clinical investigation
  • Secondary mitral regurgitation
  • Severe tricuspid regurgitation
  • A heart attack in the last year
  • Severe valve disease

Additional Info

  • The MitraClip device is currently approved by the FDA for patients who are at high-risk for traditional surgery, but is not approved for patients considered moderate to low surgical risk.
  • All treatments and physician visits during this study will take place at Anderson Medical Pavilion, Scripps La Jolla. Study participation will last up to 10 years

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org